Trial Profile
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 21 Nov 2014 New trial record